CasLoc logo
All Cases PTAB Litigations UPC Oppositions

AZURITY PHARMACEUTICALS, INC. v. NOVITIUM PHARMA, LLC

1:23-cv-00163

Overview

Case Number 1:23-cv-00163
Filing Date 2023-02-14
Status Terminated
Termination Date 2024-04-08
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 15:1126 Patent Infringement
Jury Demand None

Parties

Defendant

Novitium Pharma LLC Operating Company

Represented By

6 Attorneys Listed

Roshan P. Shrestha

Email: rshrestha@taftlaw.com

Megan C. Haney

Phillips, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200
Fax: +1 (302) 655-4210

Phillips, McLaughlin & Hall, P.A., DE

Luke T. Shannon

Email: lshannon@taftlaw.com

Andrew M. Alul

Email: aalul@taftlaw.com

Aaron M. Johnson

Email: ajohnson@taftlaw.com

John C. Phillips , Jr.

Phillips, McLaughlin & Hall, P.A.

Tel: +1 (302) 655-4200

Phillips, McLaughlin & Hall, P.A., 1200 N. Broom St

Plaintiff

Azurity Pharmaceuticals, Inc. Operating Company

Represented By

1 Attorneys Listed

Megan Elizabeth Dellinger

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 351-9366

1201 North Market Street, P.O. Box 1347

Intervenor Defendant

Bionpharma Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 13 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 1 proceeding
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (13): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (1 found):
U.S. Courts: 1
U.S. District Court 2021-10-27
1:21-cv-01522

Azurity Pharmaceuticals, Inc. v. CoreRx, Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US11040023
Enalapril formulations
Filed: 2021-01-15
Issued: 2021-06-22
Active (14.2 yrs remaining)
Expires: 2041-01-15
US11141405
Enalapril formulations
Filed: 2021-04-12
Issued: 2021-10-12
Active (9.3 yrs remaining)
Expires: 2036-03-25

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th Year Maintenance Fee Paid (8th Year Window Upcoming).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

11

Dispositive

9

Granted

4

Denied

0

Pending / Review

7

Motions by Category

Procedural / Extension Motion 2 Motion to Transfer Venue (28 U.S.C. Β§ 1404) 9

Key Dispositive Motions & Rulings

Motion to Transfer Venue (28 U.S.C. Β§ 1404) Granted
OPINION AND ORDER granting 10 Motion to Transfer Case to United States District Court for the District of Delaware; Administratively terminating 8 Motion to Int...
Entry #40 • 2023-01-20 Document →
Motion to Transfer Venue (28 U.S.C. Β§ 1404) Pending / Under Review
Letter from Arnold B. Calmann, Esq. to the Honorable Edward S. Kiel, U.S.M.J. Requesting Unsealing of Azurity's Opposition Motion to Transfer re 26 Brief in Opp...
Entry #36 • 2022-11-30 Document →
Motion to Transfer Venue (28 U.S.C. Β§ 1404) Pending / Under Review
REPLY BRIEF to Opposition to Motion filed by BIONPHARMA INC., NOVITIUM PHARMA, LLC re 10 MOTION to Transfer Case to District of Delaware (Attachments: # 1 Decla...
Entry #35 • 2022-11-18 Document →
Motion to Transfer Venue (28 U.S.C. Β§ 1404) Granted
LETTER ORDER granting Defendant's 32 Letter request for an extension to 11/21/2022 of the deadlines for Bionpharma's reply in support of its Motion to Intervene...
Entry #33 • 2022-11-14 Document →
Motion to Transfer Venue (28 U.S.C. Β§ 1404) Pending / Under Review
BRIEF in Opposition filed by AZURITY PHARMACEUTICALS, INC. re 10 MOTION to Transfer Case to District of Delaware (CALMANN, ARNOLD)NOTICE TO COUNSEL: Counsel is ...
Entry #26 • 2022-11-03 Document →
Motion to Transfer Venue (28 U.S.C. Β§ 1404) Pending / Under Review
DECLARATION of Natalie J. Morgan in Support of Azurity's Oppositions to Bionpharma's Motion to Intervene and Bionpharma's and Novitium's Motion to Transfer re 2...
Entry #27 • 2022-11-03 Document →

Docket Entries

(82 total)
Pleading / Complaint

COMPLAINT against NOVITIUM PHARMA, LLC ( Filing and Admin fee $ 402 receipt number ANJDC-13732565), filed by AZURITY PHARMACEUTICALS, INC.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Civil Cover Sheet)(CALMANN, ARNOLD) [Transferred from New Jersey on 2/14/2023.] (Entered: 10/03/2022)

Entry #1 • 2022-10-03
1
Pleading / Complaint

COMPLAINT against NOVITIUM PHARMA, LLC ( Filing and Admin fee $ 402 receipt number ANJDC-13732565), filed by AZURITY PHARMACEUTICALS, INC.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Civil Cover Sheet)(CALMANN, ARNOLD) [Transferred from New Jersey on 2/14/2023.] (Entered: 10/03/2022)

Entry #1 • 2022-10-03
2
Pleading / Complaint

COMPLAINT against NOVITIUM PHARMA, LLC ( Filing and Admin fee $ 402 receipt number ANJDC-13732565), filed by AZURITY PHARMACEUTICALS, INC.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Civil Cover Sheet)(CALMANN, ARNOLD) [Transferred from New Jersey on 2/14/2023.] (Entered: 10/03/2022)

Entry #1 • 2022-10-03
2
Pleading / Complaint

COMPLAINT against NOVITIUM PHARMA, LLC ( Filing and Admin fee $ 402 receipt number ANJDC-13732565), filed by AZURITY PHARMACEUTICALS, INC.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Civil Cover Sheet)(CALMANN, ARNOLD) [Transferred from New Jersey on 2/14/2023.] (Entered: 10/03/2022)

Entry #1 • 2022-10-03
2
Pleading / Complaint

COMPLAINT against NOVITIUM PHARMA, LLC ( Filing and Admin fee $ 402 receipt number ANJDC-13732565), filed by AZURITY PHARMACEUTICALS, INC.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Civil Cover Sheet)(CALMANN, ARNOLD) [Transferred from New Jersey on 2/14/2023.] (Entered: 10/03/2022)

Entry #1 • 2022-10-03
2

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc